| European Case Law Identifier: | ECLI:EP:BA:2012:T176011.20121113 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 13 November 2012 | ||||||||
| Case number: | T 1760/11 | ||||||||
| Application number: | 00108480.5 | ||||||||
| IPC class: | C07D 401/12 A61K 31/44 A61P 1/04 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Magnesium salt of the (-)-enantiomer of omeprazole and its use | ||||||||
| Applicant name: | AstraZeneca AB | ||||||||
| Opponent name: | Hexal AG Teva Pharmaceutical Industries Mepha AG STADA Arzneimittel AG Pinewood Laboratories Limited ETHYPHARM Actavis Group hf. Lupin Limited Zentiva a.s. Generics [UK] Limited Ratiopharm GmbH lA Pharma GmbH Hexal Pharma GmbH Hörnchen, Ulrich, Dr. |
||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Admissibility of first partiality objection (yes), second (no) Res judicata (no) Main request, added matter (yes) Auxiliary request 1, allowable Added matter (no) Sufficiency (yes), starting material retrievable from Chemical Abstracts Novelty (yes), specific salt Inventive step (yes), post-published evidence (yes), unexpected advantage Referral to the Enlarged Board of Appeal (no) Objection under Rule 106 EPC dismissed |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: https://www.epo.org/law-practice/case-law-appeals/advanced-search.html
Date retrieved: 17 May 2021